September 13, 2017 / 11:16 AM / 2 months ago

BRIEF-GTx announces positive results from enobosarm Phase 2 proof-of-concept clinical trial

Sept 13 (Reuters) - Gtx Inc

* GTx announces positive results from enobosarm phase 2 proof-of-concept clinical trial in women with stress urinary incontinence

* GTx Inc - ‍clinically significant reductions in incontinence episodes per day in all patients completing 12 week treatment​

* GTx Inc - ‍reductions in incontinence episodes were sustained for up to 7 months following completion of enobosarm treatment​

* GTx Inc - ‍mean stress leaks decreased by 83 percent from baseline over 12 weeks in study​

* GTx Inc - ‍at all evaluated dose levels, enobosarm was observed to be generally safe and well tolerated​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below